Clinical trials: completed, sponsored by Janssen Research & Development, LLC
Healthy
A Study of JNJ-70033093 (BMS-986177) in Healthy Chinese Adult Participants
The purpose of the study is to characterize the pharmacokinetics of single and multiple doses of JNJ-70033093 (BMS-986177) in healthy Chinese participants.
- Trial name
- NCT04569695
- Testing
- JNJ-70033093
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Single Ascending Dose Study of JNJ-88260237 in Healthy Participants
The purpose of this study is to assess the safety and tolerability of a single oral dose of JNJ-88260237 in healthy participants
- Trial name
- NCT05541315
- Testing
- JNJ-88260237
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants
The purpose of this study is to demonstrate bioequivalence on the primary pharmacokinetic (PK) parameters of tadalafil administered as an fixed dose combination (FDC) (test) of macitentan/tadalafil (10 milligram [mg]/40 mg) and…
- Trial name
- NCT04235270
- Testing
- FDC of Macitentan and Tadalafil, Macitentan, Tadalafil
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Fatty Liver Disease
A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795
The purpose of the study is to assess the safety and tolerability of single and multiple subcutaneous (SC) doses of JNJ-75220795.
- Trial name
- NCT04844450
- Testing
- JNJ-75220795
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study of JNJ-70033093 in Healthy Participants
The purpose of this study is to evaluate the pharmacokinetics (PK) and relative bioavailability of a single dose of JNJ-70033093 spray dried dispersion (SDD) tablets compared with JNJ-70033093 SDD granule capsules in healthy…
- Trial name
- NCT04448964
- Testing
- JNJ-70033093
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Heart Failure
A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure
The purpose of this study is to determine the superiority of the effectiveness of canagliflozin 100 milligram (mg) daily versus placebo in participants with symptomatic heart failure (HF) in improving the overall Kansas City…
- Trial name
- CHIEF-HF (NCT04252287)
- Testing
- Canagliflozin 100 mg
- Where
- 18 sites in United States
- Volunteers
- 476 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
Study to Estimate How Common it is to Have Genetic Variants Associated With NAFLD
The purpose of this study is to estimate the prevalence of genetic variants associated with liver disease in participants who are known, or are likely to have NAFLD.
- Trial name
- NCT04494360
- Testing
- No intervention
- Where
- 3 sites in United States
- Volunteers
- 830 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge
The purpose of the study is to characterize the inflammatory response to lipopolysaccharide (LPS; molecules that contains fats and carbohydrates) in the presence of a targeted immune pathway modulator.
- Trial name
- NCT05884242
- Testing
- Adalimumab, Lipopolysaccharide (LPS)
- Where
- Belgium
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
This is a 73-day phase II, open label trial of the true human monoclonal antibody RA-18C3 in subjects with moderate to severe plaque psoriasis. Ten (10) subjects will receive 200 mg of RA-18C3 via subcutaneous injection.
- Trial name
- NCT01384630
- Testing
- RA-18C3
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study of JNJ-70033093 and Digoxin in Healthy Participants
The purpose of this study is to evaluate the potential pharmacokinetic (PK) interaction between JNJ-70033093 and digoxin in healthy participants after single dose administration and at steady state.
- Trial name
- NCT04206488
- Testing
- JNJ-70033093, Digoxin
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Arthroplasty, Replacement, Knee
A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery
The purpose of this study is to determine the efficacy of JNJ-70033093 in preventing total venous thromboembolism (VTE) events (proximal and/or distal deep vein thrombosis [DVT] [asymptomatic confirmed by venography assessment or…
- Trial name
- AXIOMATIC-TKR (NCT03891524)
- Testing
- JNJ-70033093 25 mg, JNJ-70033093 50 mg, JNJ-70033093 100 mg
- Where
- 117 sites in United States, Argentina and 16 more
- Volunteers
- 1,242 people
- Sponsor
- Janssen Research & Development, LLC
Patients Undergoing Repeat Peripheral Artery Revascularization
Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis.
The purpose of this study is to determine if CV-18C3 will reduce the rate of restenosis or the time to restenosis in patients undergoing repeat peripheral artery revascularization versus controls randomized to standard of care.
- Trial name
- NCT01270945
- Testing
- CV-18C3, Standard of Care
- Where
- 8 sites in United States
- Volunteers
- 43 people
- Sponsor
- Janssen Research & Development, LLC
Dry Age-related Macular Degeneration
Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59
Age related macular degeneration (AMD) is the leading cause of vision loss in individuals over age 60. AMD is classified as wet and dry.
- Trial name
- NCT03144999
- Testing
- AAVCAGsCD59
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants
The purpose of this study is to assess the effect of nipocalimab treatment on the antibody (a protein made in the body to response to a foreign substance) response following tetanus, diphtheria, pertussis (Tdap) vaccination in…
- Trial name
- NCT05827874
- Testing
- Nipocalimab, Tdap, PPSV23
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Myelodysplastic Syndromes
Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
The main purpose of the study is to evaluate the efficacy (transfusion independence [TI]) of talacotuzumab (JNJ-56022473) or daratumumab in transfusion-dependent participants with low or intermediate-1 risk Myelodysplastic…
- Trial name
- NCT03011034
- Testing
- Talacotuzumab, Daratumumab
- Where
- 21 sites in United States, Belgium and 4 more
- Volunteers
- 34 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants
The primary purpose of this study is to assess the effect of nipocalimab on the pharmacokinetic (PK) of etanercept (Part 1); and to assess the effect of hydroxychloroquine (HCQ) on total serum immunoglobin G (IgG) reduction by…
- Trial name
- NCT04973566
- Testing
- Nipocalimab, Etanercept, Hydroxychloroquine
- Where
- Netherlands
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Prostatic Neoplasms
A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer
The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-80038114 in Part 1 (dose escalation) and to determine the safety at the RP2D(s) in Part 2 (dose expansion).
- Trial name
- NCT05441501
- Testing
- JNJ-80038114
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 39 people
- Sponsor
- Janssen Research & Development, LLC
Acute Respiratory Viral Infection
A Study to Investigate Acute Respiratory Virus Infections in Participants at High Risk for Severe Illness
The purpose of the study is to describe the rate of occurrence of clinical diagnosis of acute respiratory infection (an infection that affects normal breathing) and different types of respiratory pathogens (harmful organisms) of…
- Trial name
- BREEZE (NCT05661604)
- Testing
- No Intervention
- Where
- 4 sites in United States, Canada
- Volunteers
- 140 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer…
- Trial name
- NCT00887198
- Testing
- Abiraterone acetate, Prednisone
- Where
- 134 sites in United States, Australia and 9 more
- Volunteers
- 1,088 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
The purpose of this study is to determine if the addition of daratumumab to lenalidomide-bortezomib-dexamethasone (RVd) will increase the proportion of participants achieving stringent complete response (sCR), as defined by the…
- Trial name
- NCT02874742
- Testing
- Lenalidomide, Bortezomib, Dexamethasone
- Where
- 36 sites in United States
- Volunteers
- 224 people
- Sponsor
- Janssen Research & Development, LLC